These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 15322171)

  • 1. Prevention of diabetes in nonobese diabetic mice mediated by CD1d-restricted nonclassical NKT cells.
    Duarte N; Stenström M; Campino S; Bergman ML; Lundholm M; Holmberg D; Cardell SL
    J Immunol; 2004 Sep; 173(5):3112-8. PubMed ID: 15322171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD1d-specific NK1.1+ T cells with a transgenic variant TCR.
    Sköld M; Faizunnessa NN; Wang CR; Cardell S
    J Immunol; 2000 Jul; 165(1):168-74. PubMed ID: 10861049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Up-regulation of CD1d expression restores the immunoregulatory function of NKT cells and prevents autoimmune diabetes in nonobese diabetic mice.
    Falcone M; Facciotti F; Ghidoli N; Monti P; Olivieri S; Zaccagnino L; Bonifacio E; Casorati G; Sanvito F; Sarvetnick N
    J Immunol; 2004 May; 172(10):5908-16. PubMed ID: 15128771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The natural killer T lymphocyte: a player in the complex regulation of autoimmune diabetes in non-obese diabetic mice.
    Cardell SL
    Clin Exp Immunol; 2006 Feb; 143(2):194-202. PubMed ID: 16412042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A subset of NKT cells that lacks the NK1.1 marker, expresses CD1d molecules, and autopresents the alpha-galactosylceramide antigen.
    Hameg A; Apostolou I; Leite-De-Moraes M; Gombert JM; Garcia C; Koezuka Y; Bach JF; Herbelin A
    J Immunol; 2000 Nov; 165(9):4917-26. PubMed ID: 11046017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human invariant V alpha 24-J alpha Q TCR supports the development of CD1d-dependent NK1.1+ and NK1.1- T cells in transgenic mice.
    Capone M; Cantarella D; Schümann J; Naidenko OV; Garavaglia C; Beermann F; Kronenberg M; Dellabona P; MacDonald HR; Casorati G
    J Immunol; 2003 Mar; 170(5):2390-8. PubMed ID: 12594262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD1d-restricted NKT cells: an interstrain comparison.
    Hammond KJ; Pellicci DG; Poulton LD; Naidenko OV; Scalzo AA; Baxter AG; Godfrey DI
    J Immunol; 2001 Aug; 167(3):1164-73. PubMed ID: 11466330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Surface receptors identify mouse NK1.1+ T cell subsets distinguished by function and T cell receptor type.
    Stenström M; Sköld M; Ericsson A; Beaudoin L; Sidobre S; Kronenberg M; Lehuen A; Cardell S
    Eur J Immunol; 2004 Jan; 34(1):56-65. PubMed ID: 14971030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular profiling reveals distinct functional attributes of CD1d-restricted natural killer (NK) T cell subsets.
    Rolf J; Berntman E; Stenström M; Smith EM; Månsson R; Stenstad H; Yamagata T; Agace W; Sigvardsson M; Cardell SL
    Mol Immunol; 2008 May; 45(9):2607-20. PubMed ID: 18304639
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testing the NKT cell hypothesis of human IDDM pathogenesis.
    Lee PT; Putnam A; Benlagha K; Teyton L; Gottlieb PA; Bendelac A
    J Clin Invest; 2002 Sep; 110(6):793-800. PubMed ID: 12235110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Control of NKT cell differentiation by tissue-specific microenvironments.
    Yang Y; Ueno A; Bao M; Wang Z; Im JS; Porcelli S; Yoon JW
    J Immunol; 2003 Dec; 171(11):5913-20. PubMed ID: 14634102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of natural killer T cells protects Valpha14- Jalpha281 transgenic nonobese diabetic mice against diabetes.
    Lehuen A; Lantz O; Beaudoin L; Laloux V; Carnaud C; Bendelac A; Bach JF; Monteiro RC
    J Exp Med; 1998 Nov; 188(10):1831-9. PubMed ID: 9815260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Invariant NKT cells regulate experimental autoimmune encephalomyelitis and infiltrate the central nervous system in a CD1d-independent manner.
    Mars LT; Gautron AS; Novak J; Beaudoin L; Diana J; Liblau RS; Lehuen A
    J Immunol; 2008 Aug; 181(4):2321-9. PubMed ID: 18684921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Donor bone marrow type II (non-Valpha14Jalpha18 CD1d-restricted) NKT cells suppress graft-versus-host disease by producing IFN-gamma and IL-4.
    Kim JH; Choi EY; Chung DH
    J Immunol; 2007 Nov; 179(10):6579-87. PubMed ID: 17982047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of a nonclassical NKT cell subset in a transgenic mouse model of hepatitis B virus infection.
    Baron JL; Gardiner L; Nishimura S; Shinkai K; Locksley R; Ganem D
    Immunity; 2002 Apr; 16(4):583-94. PubMed ID: 11970881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immediate antigen-specific effector functions by TCR-transgenic CD8+ NKT cells.
    Wingender G; Berg M; Jüngerkes F; Diehl L; Sullivan BA; Kronenberg M; Limmer A; Knolle PA
    Eur J Immunol; 2006 Mar; 36(3):570-82. PubMed ID: 16506291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells.
    Metelitsa LS; Naidenko OV; Kant A; Wu HW; Loza MJ; Perussia B; Kronenberg M; Seeger RC
    J Immunol; 2001 Sep; 167(6):3114-22. PubMed ID: 11544296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD1d-independent developmental acquisition of prompt IL-4 gene inducibility in thymus CD161(NK1)-CD44lowCD4+CD8- T cells is associated with complementarity determining region 3-diverse and biased Vbeta2/Vbeta7/Vbeta8/Valpha3.2 T cell receptor usage.
    Chen YT; Kung JT
    J Immunol; 2005 Nov; 175(10):6537-50. PubMed ID: 16272308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phenotypic and functional differences between NKT cells colonizing splanchnic and peripheral lymph nodes.
    Laloux V; Beaudoin L; Ronet C; Lehuen A
    J Immunol; 2002 Apr; 168(7):3251-8. PubMed ID: 11907079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD4(+) type II NKT cells mediate ICOS and programmed death-1-dependent regulation of type 1 diabetes.
    Kadri N; Korpos E; Gupta S; Briet C; Löfbom L; Yagita H; Lehuen A; Boitard C; Holmberg D; Sorokin L; Cardell SL
    J Immunol; 2012 Apr; 188(7):3138-49. PubMed ID: 22371394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.